Abstracts tagged "Psoriatic arthritis"

Abstract Number: 0905 • ACR Convergence 2020
Probability of Achieving Low Disease Activity or Remission with Apremilast Treatment Among DMARD-Naive Subjects with Active Psoriatic Arthritis
Philip Mease¹, Arthur Kavanaugh², Alexis Ogdie³, Alvin Wells⁴, Martin Bergman⁵, Dafna Gladman⁶, Frank Behrens⁷, Sven Richter⁸, Michele Brunori⁹, Lichen Teng⁸, Benoit Guerette⁸ and Josef Smolen¹⁰, ¹Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ²UC San Diego Health System, San Diego, CA, ³Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁴Aurora Rheumatology and Immunotherapy Center, Franklin, ⁵Drexel University College of Medicine, Philadelphia, PA, ⁶Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁷CIRI/Rheumatology & Fraunhofer IME, Research Division Translational Medicine and Pharmacology, Goethe University Hospital, Frankfurt, Hessen, Germany, ⁸Amgen Inc., Thousand Oaks, ⁹Amgen Europe GmbH, Rotkreuz, Switzerland, ¹⁰Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria
Background/Purpose: Apremilast (APR) is associated with comparable ACR response rates in DMARD-naive vs DMARD-experienced patients (pts) with PsA (Wells AF, et al. Rheumatology. 2018;57:1253-63; Kavanaugh…
Abstract Number: 1328 • ACR Convergence 2020
Cardiac Biomarkers Are Associated with the Development of Cardiovascular Events in Patients with Psoriatic Arthritis and Psoriasis
Keith Colaco¹, Ker-Ai Lee², Shadi Akhtari³, Raz Winer⁴, Paul Welsh⁵, Naveed Sattar⁵, Iain McInnes⁶, Vinod Chandran⁷, Paula Harvey⁸, Richard Cook², Dafna Gladman⁷, Vincent Piguet⁸ and Lihi Eder⁹, ¹Institute of Medical Science, University of Toronto; Women's College Research Institute, Women's College Hospital; and Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ²University of Waterloo, Waterloo, ON, Canada, ³Women's College Hospital, University of Toronto, North York, ON, Canada, ⁴Rambam Health Care Campus, Haifa, Israel, ⁵University of Glasgow, Glasgow, Scotland, United Kingdom, ⁶Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁷Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁸Women's College Hospital, University of Toronto, Toronto, ON, Canada, ⁹Women’s College Research Institute, University of Toronto, Toronto, ON, Canada
Background/Purpose: N-terminal pro-brain-type natriuretic peptide (NT-proBNP) and troponin I (TnI) are established cardiac biomarkers that predict cardiovascular events (CVEs) and mortality in apparently healthy individuals…
Abstract Number: 1355 • ACR Convergence 2020
Characterization of Remission in Patients with Psoriatic Arthritis Treated with Upadacitinib: Post-hoc Analysis from Two Phase 3 Trials
Philip Mease¹, Arthur Kavanaugh², Dafna Gladman³, Oliver FitzGerald⁴, Enrique Soriano⁵, Peter Nash⁶, Dai Feng⁷, Apinya Lertratanakul⁷, Kevin Douglas⁸, Ralph Lippe⁹ and Laure Gossec¹⁰, ¹Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ²Division of Rheumatology, Allergy, & Immunology, University of California San Diego Medical School, San Diego, CA, ³Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁴Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland, ⁵Department of Public Health, Instituto Universitario, Escuela de Medicina Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, Capital Federal, Buenos Aires, Argentina, ⁶School of Medicine Griffith University, Brisbane, Queensland, Australia, ⁷AbbVie Inc., North Chicago, IL, ⁸AbbVie Inc., North Chicago, ⁹AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ¹⁰Sorbonne Université and Hôpital Universitaire Pitié Salpêtrière, Paris, France
Background/Purpose: Treat-to-target strategies in PsA recommend aiming for remission or low disease activity (LDA). Several disease activity measures are available including very low/minimal disease activity…
Abstract Number: 1549 • ACR Convergence 2020
Joint Damage and Malalignment Determine Articular Tenderness More Than Inflammation in Rheumatoid Arthritis, Psoriatic Arthritis or Osteoarthritis in Established Disease
Mihaela Popescu¹, Victoria Schimpl², Gabriela Supp³, Martina Durechova³, Paul Studenic³, Michael Zauner³, Josef Smolen³, Daniel Aletaha⁴, Peter Mandl³ and Irina Gessl³, ¹Hôpital Maisonneuve-Rosemont, Montreal, Canada, ²Medical University of Vienna, Vienna, Austria, ³Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria, ⁴Division of Rheumatology, Department of Medicine III, Medical University of Vienna,, Vienna, Austria
Background/Purpose: To determine whether clinical tenderness can be considered a sign of inflammatory joint activity in patients with rheumatoid arthritis (RA), osteoarthritis (OA) or psoriatic…
Abstract Number: 2021 • ACR Convergence 2020
The Reliability of Scoring Sonographic Entheseal Abnormalities – the Diagnostic Ultrasound Enthesitis Tool (DUET) Study
Lihi Eder¹, Sibel Aydin² and Gurjit Kaeley³, ¹Women’s College Research Institute, University of Toronto, Toronto, ON, Canada, ²University of Ottawa Faculty of Medicine, Rheumatology, Ottawa, ON, CANADA; The Ottawa Hospital Research Institute, Ottawa, ON, CANADA, Ottawa, ON, Canada, ³University of Florida College of Medicine - Jacksonville, Jacksonville, FL
Background/Purpose: DUET is a study supported by the Group for Assessment for Psoriasis and Psoriatic Arthritis (GRAPPA) that aims to develop a novel sonographic scoring…
Abstract Number: 0163 • ACR Convergence 2020
Cost of Non-Persistence in the Treatment with Subcutaneous Tumor Necrosis Factor-Alpha Inhibitors of Inflammatory Arthritis: A Propensity Score Matching Approach
Johan Dalén¹, Karin Luttropp¹, Tor Olofsson², Christopher Black³ and Amy Puenpatom⁴, ¹ICON plc, Stockholm, Sweden, Stockholm, Sweden, ²Department of Clinical Sciences, Lund, Rheumatology, Lund University, Sweden; Department of Rheumatology, Skåne University Hospital, Lund, Sweden, Lund, Sweden, ³Merck & Co., Inc., Kenilworth, NJ, USA, Rahway, NJ, ⁴Merck & Co., Inc., Kenilworth, NJ, USA, North Wales, PA
Background/Purpose: Few studies have explored cost consequences of non-persistence in the treatment with Subcutaneous Tumor Necrosis Factor-Alpha Inhibitors (SC-TNFi) in Inflammatory Arthritis (IA; rheumatoid arthritis…
Abstract Number: 0316 • ACR Convergence 2020
High-sensitivity 18F-FDG PET/CT: A Diagnostic Tool for Psoriatic Arthritis
Siba Raychaudhuri¹, Yasser Abdelhafez², Soumajyoti Sarkar³, Smriti Raychaudhuri⁴ and Abhijit Chaudhari², ¹Division of Rheumatology, Allergy & Clinical Immunology, University of California School of Medicine, Davis, and VA Medical Center Sacramento, Sacramento, CA, ²University of California, Davis, Sacramento, CA, ³University of California, Davis, Davis, ⁴VA Sacramento Medical Center, Davis, CA
Background/Purpose: To validate high-sensitivity PET/CT as a diagnostic test we have explored the association of total-body and extremity PET/CT measures with the standardized psoriatic arthritis…
Abstract Number: 0332 • ACR Convergence 2020
Guselkumab Improved Work Productivity and Daily Activity in Patients with Psoriatic Arthritis: Results from a Phase 3 Trial
Jeffrey R Curtis¹, Iain McInnes², Proton Rahman³, William Tillett⁴, Philip Mease⁵, Alexa Kollmeier⁶, Elizabeth Hsia⁷, Bei Zhou⁸, Prasheen Agarwal⁸, Steven Peterson⁹ and Chenglong Han⁸, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ³Memorial University of Newfoundland, Department of Medicine, St John's, Canada, ⁴Royal National Hospital for Rheumatic Diseases, Bath, UK; Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, ⁵Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ⁶Janssen Research & Development, LLC, La Jolla, CA, ⁷Janssen Research & Development, LLC and University of Pennsylvania Medical Center, Spring House, PA, ⁸Janssen Research & Development, LLC, Spring House, PA, ⁹Janssen Immunology Global Commercial Strategy Organization, Horsham, PA
Background/Purpose: DISCOVER 2 (DISC 2) is a Phase 3 trial of anti-IL-23-specific MAb Guselkumab (GUS) in PsA patients, who experience impaired physical function, resulting in…
Abstract Number: 0352 • ACR Convergence 2020
Efficacy and Safety of Ixekizumab versus Adalimumab with and Without Concomitant Conventional Synthetic Disease-Modifying Antirheumatic Drugs (DMARD) in Biologic DMARD-Naïve Patients with Psoriatic Arthritis: 52-Week Results
Josef Smolen¹, Anthony Sebba², Eric Ruderman³, Amanda Gellett⁴, Christophe Sapin⁴, Aubrey Sprabery⁴, Soyi Liu-Leage⁴, Sreekumar Pillai⁴, Paulo Reis⁴ and Peter Nash⁵, ¹Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria, ²Arthritis Associates, Palm Harbor, Tampa, FL, ³Feinberg School of Medicine, Northwestern University, Chicago, IL, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵School of Medicine Griffith University, Brisbane, Queensland, Australia
Background/Purpose: Ixekizumab (IXE), a high-affinity monoclonal antibody selectively targeting IL-17A, was superior to adalimumab (ADA) at Week (Wk) 24 for simultaneous achievement of ACR50 and…
Abstract Number: 0379 • ACR Convergence 2020
Achievement of RAPID3 and cDAPSA Treatment Targets Is Associated with Control of Articular and Extra-Articular Manifestations of Active Psoriatic Arthritis in DMARD-Naive Patients Treated with Apremilast
Philip Mease¹, Arthur Kavanaugh², Alexis Ogdie³, Alvin Wells⁴, Martin Bergman⁵, Dafna Gladman⁶, Sven Richter⁷, Michele Brunori⁸, Lichen Teng⁷, Benoit Guerette⁷ and Josef Smolen⁹, ¹Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ²UC San Diego Health System, San Diego, CA, ³University of Pennsylvania, Philadelphia, PA, ⁴Aurora Rheumatology and Immunotherapy Center, Franklin, ⁵Drexel University College of Medicine, Philadelphia, PA, ⁶Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁷Amgen Inc., Thousand Oaks, ⁸Amgen Europe GmbH, Rotkreuz, Switzerland, ⁹Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria
Background/Purpose: Phase III PALACE 4 (NCT01307423) assessed the efficacy of apremilast (APR) in DMARD-naive patients with PsA. The Routine Assessment of Patient Index Data 3…
Abstract Number: 0805 • ACR Convergence 2020
The PROPER Study: Results of the First Interim Analysis of a Pan-EU Real-World Study of SB5 Biosimilar Following Transition from Reference Adalimumab in Patients with Rheumatoid Arthritis, Axial Spondyloarthritis or Psoriatic Arthritis
Ulf Müller-Ladner¹, Karl Gaffney², Deepak Jadon³, Ulrich Freudensprung⁴ and Janet Addison⁵, ¹Department of Rheumatology, Immunology, Osteology and Physical Medicine, Justus Liebig University Gießen, Campus Kerckhoff, Bad Nauheim, Germany, Bad Nauheim, Germany, ²Norfolk and Norwich University Hospital NHS Foundation Trust, Norfolk, United Kingdom, ³Cambridge University Hospitals NHSFT, Cambridge, United Kingdom, ⁴Biogen International GmbH, Baar, Switzerland, ⁵Biogen Idec, Maidenhead, United Kingdom
Background/Purpose: SB5, an adalimumab biosimilar received EU marketing authorisation in August 2017, based on the totality of evidence from pre-clinical and clinical Phase I and…
Abstract Number: 0906 • ACR Convergence 2020
Bimekizumab Treatment Is Associated with Improvements in Back Pain and Fatigue in Patients with Active Psoriatic Arthritis: 48-Week Results from a Phase 2b Study
Atul Deodhar¹, Laure Gossec², Philip Mease³, Jason Coarse⁴, Heather Edens⁵, Natasha de Peyrecave⁶, Deepak Assudani⁶, Barbara Ink⁷ and Christopher Ritchlin⁸, ¹Oregon Health & Science University, Portland, OR, ²Sorbonne Université and Hôpital Universitaire Pitié Salpêtrière, Paris, France, ³Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ⁴UCB Pharma, Raleigh, NC, ⁵UCB Pharma, Smyrna, GA, ⁶UCB Pharma, Slough, United Kingdom, ⁷UCB Pharma, Slough, ⁸Department of Medicine, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Patients (pts) with psoriatic arthritis (PsA) require effective treatment across all symptoms. Bimekizumab (BKZ) is a humanized IgG1 monoclonal antibody which selectively neutralizes interleukin…
Abstract Number: 1329 • ACR Convergence 2020
Subclinical Atherosclerosis Risk in Psoriatic Arthritis: Could It Be Prevented?
Mai Farouk¹, Salwa Moussa¹ and Rowaida Abdou¹, ¹Rhuematology Ain Shams University Hospitals, Cairo, Egypt
Background/Purpose: Psoriatic arthritis (PsA) is an immune-mediated inflammatory arthritis associated with psoriasis that can cause remarkable joint damage (1). Subclinical cardiovascular disease (CVD) due to…
Abstract Number: 1356 • ACR Convergence 2020
Efficacy of Upadacitinib in Patients with Psoriatic Arthritis Stratified by Number of Prior Biologic Disease-modifying Anti-rheumatic Drugs
Philip Mease¹, Apinya Lertratanakul², Bruce Strober³, Shigeyoshi Tsuji⁴, Pascal Richette⁵, Charlie Lovan⁶, Dai Feng², Jaclyn K Anderson² and Filip Van den Bosch⁷, ¹Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ²AbbVie Inc., North Chicago, IL, ³Yale University School of Medicine and Central Connecticut Dermatology, New Haven, ⁴Department of Orthopaedics/Rheumatology, National Hospital Organization, Osaka Minami Medical Center, Osaka, Japan, ⁵Department of Rheumatology, Lariboisière Hospital, Paris, France, ⁶AbbVie Inc., North Chicago, ⁷Ghent University Hospital, Ghent, Belgium
Background/Purpose: Upadacitinib (UPA) has shown efficacy and safety in patients (pts) with active PsA in the Phase 3 SELECT-PsA 1 and SELECT-PsA 2 clinical trials.1,2…
Abstract Number: 1552 • ACR Convergence 2020
Ultrasound Doppler Enthesitis Shows Sensitivity to Change After Biological Therapy in Spondyloarthritis and Psoriatic Arthritis Patients
Juan Molina Collada¹, Cristina Macía-Villa², Chamaida Plasencia³, Jose Maria Alvaro-Gracia⁴ and Eugenio De Miguel⁵, ¹Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²Hospital Universitario Severo Ochoa, Madrid, Spain, ³Rheumatology, La Paz University Hospital-IdiPAZ, madrid, Spain, ⁴CEIMI, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁵Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: The assessment of activity in spondyloarthritis (SpA) and psoriatic arthritis (PsA) involves several domains, including enthesitis. Clinical enthesitis has shown low sensitivity, specificity and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].